Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
6 papers
Recent·Most cited
L. Zhang, J. I. Hsu, E. D. Braekeleer…·M. A. Goodell
This study identifies SOD1 as a synthetic lethal target in PPM1D-mutant leukemia cells through CRISPR/Cas9 screening, revealing a dysregulated redox landscape and potential therapeutic strategy.
K. Woodley, L. S. Dillingh, G. Giotopoulos…·P. Gallipoli
This study shows that inhibiting mannose metabolism sensitizes AML cells to cytarabine and FLT3 inhibitors by promoting ferroptotic cell death through fatty acid metabolism changes.
S. Gupta, O. M. Dovey, A. F. Domingues…·C. Pina
Loss of Kat2a enhances transcriptional variability of ribosome biosynthetic programs and transiently accelerates pre-leukemia.
M. A. Fabre, J. G. de Almeida, E. Fiorillo…·G. S. Vassiliou
This study tracks clonal haematopoiesis clones over time, finding that mutation type influences growth rates and malignant risk.
Y. Z. Au, M. Gu, E. De Braekeleer…·K. Yusa
This study identifies KAT7 as a critical therapeutic target in MLL-rearranged AML by showing its role in maintaining acetylation marks and supporting cell proliferation.
H. Yun, S. Vohra, A. Mupo…·B. J. P. Huntly
The paper investigates how mutations synergize to alter chromatin accessibility, enhancer landscapes, and 3D DNA topology in leukemia induction using a murine model.